Zobrazeno 1 - 10
of 225
pro vyhledávání: '"Peter J Lenting"'
Autor:
Elena Barbon, Gabriel Ayme, Amel Mohamadi, Jean‐François Ottavi, Charlotte Kawecki, Caterina Casari, Sebastien Verhenne, Solenne Marmier, Laetitia van Wittenberghe, Severine Charles, Fanny Collaud, Cecile V Denis, Olivier D Christophe, Federico Mingozzi, Peter J Lenting
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 4, Pp n/a-n/a (2020)
Abstract Novel therapies for hemophilia, including non‐factor replacement and in vivo gene therapy, are showing promising results in the clinic, including for patients having a history of inhibitor development. Here, we propose a novel therapeutic
Externí odkaz:
https://doaj.org/article/4434607219fc41c0b6465b55049e9dff
Autor:
Eliane Berrou, Alexandre Kauskot, Frédéric Adam, Amélie Harel, Paulette Legendre, Cécile Lavenu Bombled, Chantal Rothschild, Nicolas Prevost, Olivier D Christophe, Peter J Lenting, Cécile V Denis, Jean-Philippe Rosa, Marijke Bryckaert
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0143896 (2015)
Thrombocytopenia and increased platelet clearance observed in von Willebrand disease-type 2B (VWD-2B) may be explained by platelet apoptosis triggered by the constitutive binding of VWF to its receptor, glycoprotein Ib (GPIb). Apoptosis was assessed
Externí odkaz:
https://doaj.org/article/d8e2b4c2a0aa4289808c2ba24a245f90
Publikováno v:
PLoS ONE, Vol 7, Iss 9, p e45111 (2012)
Factor X (FX), a plasma glycoprotein playing a central role in coagulation has a long circulatory half-life compared to closely related coagulation factors. The activation peptide of FX has been shown to influence its clearance with two N-glycans as
Externí odkaz:
https://doaj.org/article/998d4d7e17784cbd9818af40362ee833
Autor:
Idinath Badirou, Mohamad Kurdi, Paulette Legendre, Julie Rayes, Marijke Bryckaert, Caterina Casari, Peter J Lenting, Olivier D Christophe, Cecile V Denis
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e37508 (2012)
The objective of this project was to study the function of O-glycosylations in von Willebrand factor (VWF) life cycle. In total, 14 different murine Vwf cDNAs mutated on one or several O-glycosylations sites were generated: 9 individual mutants, 2 do
Externí odkaz:
https://doaj.org/article/80df049f5c7640ac911c0da116a643b6
Autor:
Martine J Hollestelle, Ka Wai Lai, Marcel van Deuren, Peter J Lenting, Philip G de Groot, Tom Sprong, Niels Bovenschen
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e24216 (2011)
Von Willebrand factor (VWF) is a pro-hemostatic multimeric plasma protein that promotes platelet aggregation and stabilizes coagulation factor VIII (FVIII) in plasma. The metalloproteinase ADAMTS13 regulates the platelet aggregation function of VWF v
Externí odkaz:
https://doaj.org/article/302eb4089977461eb7ca781cb88986a5
Autor:
Robert H E Friesen, Wouter Koudstaal, Martin H Koldijk, Gerrit Jan Weverling, Just P J Brakenhoff, Peter J Lenting, Koert J Stittelaar, Albert D M E Osterhaus, Ronald Kompier, Jaap Goudsmit
Publikováno v:
PLoS ONE, Vol 5, Iss 2, p e9106 (2010)
BackgroundThe urgent medical need for innovative approaches to control influenza is emphasized by the widespread resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the occurrences of
Externí odkaz:
https://doaj.org/article/a18d9b465c634aafa91631ed935c70d4
Publikováno v:
PLoS ONE, Vol 5, Iss 8, p e12174 (2010)
LAIR-1 (Leukocyte Associated Ig-like Receptor -1) is a collagen receptor that functions as an inhibitory receptor on immune cells. It has a soluble family member, LAIR-2, that also binds collagen and can interfere with LAIR-1/collagen interactions. C
Externí odkaz:
https://doaj.org/article/98ea3b8ee6a440e691e7944604890759
Autor:
Kathelijn Fischer, Ronan Pendu, Carina J van Schooten, Karin van Dijk, Cécile V Denis, H Marijke van den Berg, Peter J Lenting
Publikováno v:
PLoS ONE, Vol 4, Iss 8, p e6745 (2009)
BACKGROUND: Von Willebrand factor (VWF) is critical for the in vivo survival of factor VIII (FVIII). Since FVIII half-life correlates with VWF-antigen pre-infusion levels, we hypothesized that VWF levels are useful to predict FVIII half-life. METHODO
Externí odkaz:
https://doaj.org/article/d8a694feac484d95ad255c101628da1c
Autor:
Thibaud Sefiane, Hortense Maynadié, Carmen Escurola Ettingshausen, Vincent Muczynski, Xavier Heiligenstein, Julien Dumont, Olivier D. Christophe, Cécile V. Denis, Caterina Casari, Peter J. Lenting
Publikováno v:
Haematologica, Vol 109, Iss 6 (2023)
Recombinant factor VIII (rFVIII), rFVIIIFc and emicizumab are established treatment options in the management of hemophilia A. Each has its unique mode of action, which can influence thrombin generation kinetics and therefore also the kinetics of thr
Externí odkaz:
https://doaj.org/article/87dfb0cfe60b4523b7deb3413f713473
Autor:
Cécile V. Denis, Peter J. Lenting
Publikováno v:
Haematologica, Vol 107, Iss 9 (2021)
Externí odkaz:
https://doaj.org/article/9b08e5499b5949308589dae04fe1485a